Neuralink's experimental 'Blindsight' device, which is designed to enable even those who have lost both eyes and their optic nerve to see, has received the US FDA's breakthrough device designation. The 'breakthrough' tag is given to certain medical devices that provide treatment for or diagnosis of life-threatening conditions. It is aimed at speeding up the development and review of devices. Neuralink is currently testing an implant designed to give paralyzed patients the ability to use digital devices by thinking - it is unknown when it expects Blindsight devices to move into human trials.